Title |
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
|
---|---|
Published in |
Blood Cancer Discovery, July 2021
|
DOI | 10.1158/2643-3230.bcd-21-0055 |
Pubmed ID | |
Authors |
Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick, Charalambos Andreadis |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 35% |
Brazil | 1 | 5% |
Hungary | 1 | 5% |
Austria | 1 | 5% |
Unknown | 10 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 45% |
Scientists | 8 | 40% |
Science communicators (journalists, bloggers, editors) | 2 | 10% |
Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 18 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 3 | 17% |
Other | 2 | 11% |
Student > Bachelor | 2 | 11% |
Student > Master | 2 | 11% |
Unspecified | 1 | 6% |
Other | 1 | 6% |
Unknown | 7 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 22% |
Medicine and Dentistry | 2 | 11% |
Arts and Humanities | 1 | 6% |
Agricultural and Biological Sciences | 1 | 6% |
Unspecified | 1 | 6% |
Other | 2 | 11% |
Unknown | 7 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 98. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2022.
All research outputs
#380,921
of 23,511,526 outputs
Outputs from Blood Cancer Discovery
#10
of 166 outputs
Outputs of similar age
#10,392
of 436,793 outputs
Outputs of similar age from Blood Cancer Discovery
#1
of 12 outputs
Altmetric has tracked 23,511,526 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 166 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,793 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.